ArticleGeneral thoracic and cardiovascular surgery2015
Multimodality treatment for advanced thymic carcinoma: outcomes of induction therapy followed by surgical resection in 16 cases at a single institution.
Article in General thoracic and cardiovascular surgery, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Induction Therapy Followed by Surgery in Advanced Thymic Epithelial Tumors: A 20-Year Systematic Review and Meta-Analysis.Oncology research · 2026Pooled it
- Trial
- Imaging-based criteria for minimally invasive versus open surgery in thymic tumors: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- Serial positron-emission tomography after induction therapy as a predictor of prognostic outcomes for patients with thymic carcinoma.Surgery today · 2025Article
- Thymic carcinoma recurring 11 years post-extended surgery: a case report.General thoracic and cardiovascular surgery cases · 2025Article
- Long-term Survival in Stage IVb Thymic Carcinoma With Multidisciplinary Aggressive Treatment.Annals of thoracic surgery short reports · 2024Article
- Current immunotherapy for thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Perioperative management and postoperative outcomes of locally advanced thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Surgical treatment of thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Surgical outcomes of patients with locally advanced thymic epithelial tumor undergoing induction therapy followed by surgery: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Narrative review of indication and management of induction therapy for thymic epithelial tumors.Mediastinum (Hong Kong, China) · 2024Review
- Surgical management of thymic epithelial tumors.Surgery today · 2021Review
- Salvage surgery for stage IVa thymic carcinoma combined with aortic arch resection - case report.Journal of cardiothoracic surgery · 2020Article
- The role of induction therapy for thymic malignancies: a narrative review.Mediastinum (Hong Kong, China) · 2020Review
- Complete resection of local advanced thymic carcinoma with total aortic arch replacement after chemotherapy: a case report.Surgical case reports · 2019Article
- Surgical approach for thymic epithelial tumor.Journal of thoracic disease · 2019Article
- Video-assisted thoracoscopy versus open approach in patients with Masaoka stage III thymic epithelial tumors.Translational cancer research · 2019Article
- Two-year disease remission of an unresectable basaloid thymic carcinoma with second line chemotherapy drugs: report of a case.The Pan African medical journal · 2019Article
- Article
- Elevated pretreatment serum lactate dehydrogenase level predicts inferior overall survival and disease-free survival after resection of thymic carcinoma.Journal of thoracic disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe reviewed our institutional experience with cases of multimodality treatment for advanced thymic carcinoma to determine patient outcomes and prognostic indicators.
methodsBetween 1998 and 2014, 16 patients with a Masaoka stage III or IV thymic carcinoma underwent surgical resection after induction therapy at Osaka University Hospital. These were considered to have great vessel invasion or metastasis to the mediastinal or intrathoracic lymph nodes based on the preoperative workup findings, and received induction therapy.
resultsComplete tumor resection was achieved in 11 (69%) after the induction therapy. Pathological findings revealed that 10 patients had Masaoka stage III disease, 1 had IVa, and 5 had IVb. The histological diagnosis was squamous cell carcinoma in 13, neuroendocrine carcinoma in 2, and undifferentiated carcinoma in 1. The 5-year survival rate for all patients was 71%. Survival was significantly better in patients who underwent a complete resection (R0 disease) as compared to those with incompletely resected tumors (R1 or R2 disease).
conclusionsMultimodality treatment offers encouraging results and complete resection provides high survival rate for patients with advanced thymic carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.